Rejected from Current Biology? The 7 Best Journals to Submit Next

Current Biology is part of the Cell Press transfer system, which is the highest-leverage detail after a rejection here. The system is author-driven and opt-in: if your decision letter contains a transfer offer, you can move the manuscript and its full review history to a sister journal, and you have 90 days to accept. Crucially, the reviews travel with the paper, so the receiving journal can reuse them and often reaches a decision faster than a fresh submission would.

The realistic ladder looks like this. Current Biology (Tier 1, broad biology + general interest) steps down to Cell Reports (still broad and cross-disciplinary, but without the general-interest bar), then to iScience (the open-access cascade target for technically rigorous broad-biology work). For organism-level or ecology and evolution work, Proceedings B is a strong lateral move outside Cell Press.

The most common Cell Press cascade across the portfolio runs Cell, then Molecular Cell or a discipline-specific title, then Cell Reports, then iScience, and a Current Biology rejection slots naturally into the back half of that ladder.

If that transfer is rejected too, or if no transfer was offered, the next tier is a broad-interest journal outside the portfolio: Nature Communications or PLOS Biology if the breadth claim is real, eLife if you want the work judged in the open. Do not treat the cascade as automatic ladder-descent.

If the rejection said the science is field-bounded rather than under-framed, a respected field journal that reaches your actual readers is often a better strategic move than a broad-biology retry, even at a lower headline metric. The best next journal is the one where your existing manuscript is easiest to evaluate fairly.

In our pre-submission review work with Current Biology submissions, the rejections we see cluster into a small number of testable patterns. Each of the named rejection patterns below maps to a specific editorial triage pattern we observe repeatedly, and each is a specific failure pattern you can check your own manuscript against before you resubmit.

Current Biology's whole editorial identity is general interest across biology, so the filter at triage is not just "is this correct and important" but "will a biologist in a different subfield care." Most of what gets returned fails that second test in a way you can check before you resubmit.

General-interest framing exists only in the cover letter. This is the single most common pattern we see in Current Biology submissions. The science is solid and the cover letter claims broad relevance, but the abstract, introduction, and figures read like a specialist paper. The consulting editor reads the manuscript itself, not the aspiration.

We see this in manuscripts where the abstract opens with subfield jargon and never states why a biologist outside the niche should read on, and where Figure 1 assumes the reader already cares about the system. Fix it by rebuilding the abstract and introduction around the broad biological question first, and the specialist mechanism second.

Current Biology's author guidance caps the abstract at 175 words and the main text of a Report at 5,000 words, so the broad framing has to do its work inside a tight space. The breadth claim has to live in the manuscript, not the letter.

Story completeness is short of Current Biology's bar. Current Biology wants a complete story, not a promising fragment, because a general-interest reader will not follow a half-finished argument. We repeatedly see Current Biology submissions where a phenotype is shown without its mechanism, or a mechanism is proposed without the rescue or epistasis experiment that would close the causal chain.

Reviewers and editors read these as incomplete rather than wrong, and at a general-interest journal incomplete is a rejection. Before resubmitting, ask whether a non-specialist could follow the claim from observation to conclusion without an act of faith. If a key control or comparison is missing, add it before you move, because the same gap will surface at the next journal too.

Subfield significance presented as general significance. A genuinely strong result in behavioral ecology, sensory neuroscience, or developmental biology that matters mostly to specialists in that exact area struggles at triage even when the work is excellent. Current Biology's editorial bar is significance across fields, not within one. We see this pattern in submissions whose discussion explains the advance entirely in specialist terms and adds the broad implication as an afterthought.

This is the cleanest signal that the paper belongs in Cell Reports, a field-specific journal, or Proceedings B rather than back in the Current Biology queue.

Statistical support thin for the breadth of the claims. Current Biology editors and reviewers screen sample sizes and statistical analysis at the level the claims demand. We regularly see manuscripts where n equals 3 biological replicates underpins a central, broadly framed conclusion without justification, or where the statistical test is mismatched to the data distribution.

A general-interest claim invites scrutiny from readers across biology, so the statistical foundation has to be stronger, not weaker, than a specialist paper would need. Tighten the analysis and the reported effect sizes before you resubmit anywhere.

Do not just blast the same file down the ladder. A Current Biology rejection is usually a framing or completeness signal, and the next journal will read the same manuscript the same way unless you change something. The honest question is whether the rejection was about reach or about substance.

If reviewers or your own read flagged a missing control, a missing comparison, or an unclosed causal chain, that is real work, not a formatting pass, and it needs to happen before you move. Resubmitting an incomplete story to Cell Reports or iScience just spends another review cycle to hear the same thing. If the rejection was purely about general-interest fit and the science is complete, then the fast move is to reframe the abstract and introduction and resubmit within days.

One more honest caveat: appeals at Current Biology rarely succeed. The decision is usually a fit judgment, not a factual dispute, and fit calls are hard to overturn. Your time is almost always better spent picking a better-matched journal than contesting the rejection. If you do decide to resubmit a revised version inside Cell Press, the originating submission system is the Current Biology portal at Cell Press journal page, and a transfer carries your file across without a fresh upload.

How we produced this guidance: the rejection patterns above are drawn from our pre-submission review work on Current Biology submissions, and the sources we checked for the venue facts (scope, APC, review timing, transfer mechanics) include the Cell Press, ScienceDirect, PLOS, eLife, Springer Nature, and Royal Society author pages, all reviewed in June 2026. Acceptance rates and fees change, so confirm the live numbers on each journal's current author page before you submit.

• How to choose a journal for your paper
• Current Biology journal guide: fit, scope, review
• What pre-submission peer review includes